New Data Will Help Predict Vision Loss In Glaucoma

Eye M.D.s are intent on finding better ways to diagnose and treat glaucoma, a complex, potentially blinding disease. September's Ophthalmology journal includes new data from the Rotterdam Study that will help doctors better predict visual field loss (VFL) in glaucoma patients. Johannes R. Vingerling, MD, PhD, Erasmus Medical Center, The Netherlands, and his colleagues followed 6,630 participants ...

FDA approves LUMIGAN for intraocular pressure reduction in open-angle glaucoma patients

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Tom Lieber - abstractionist's art looks alive

Stroke for stroke, Tom Lieber paints as well as any abstractionist out there. But he still struggles to pull paintings together, as his recent work at Dolby Chadwick demonstrates. Or perhaps his paintings show us an artist honestly at odds with his own... Painting - Visual Art - Arts - Shopping - Painters

Allergan Receives FDA Approval For LUMIGAN(R) 0.01% As First-Line Therapy Indicated For The Reduction Of Elevated ...

Allergan, Inc. (NYSE:AGN) announced the United States Food and Drug Administration (FDA) has approved LUMIGAN® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN® 0.01% is an optimized reformulation of LUMIGAN® (bimatoprost ophthalmic solution) 0.03 ...

Diabetes can lead to serious eye disorders

DUBAI — Diabetic eye disease refers to a group of eye problems that people with diabetes may face. In some cases it can cause severe vision loss or even blindness.